Sunesis reported new data on SNS-062 as and Qinprezo at the American Society of Hematology (ASH) meeting in December 2016. The Phase Ia trial of SNS-062 was completed and the company reported positive food effect data as well as an expanded safety data set without significant adverse events. New results of the Qinprezo VALOR trial were presented, demonstrating a durable response in acute myeloid leukemia (AML) patients over 60 with a median follow-up of 39.9 months.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Sunesis shines at ASH
- Published:
13 Dec 2016 -
Author:
Maxim Jacobs -
Pages:
7
Sunesis reported new data on SNS-062 as and Qinprezo at the American Society of Hematology (ASH) meeting in December 2016. The Phase Ia trial of SNS-062 was completed and the company reported positive food effect data as well as an expanded safety data set without significant adverse events. New results of the Qinprezo VALOR trial were presented, demonstrating a durable response in acute myeloid leukemia (AML) patients over 60 with a median follow-up of 39.9 months.